Quantcast

Latest Interferon beta-1a Stories

2010-04-19 08:00:00

WALTHAM, Mass., April 19 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that early lines of therapy for the treatment of multiple sclerosis are dominated by Teva's Copaxone and Biogen Idec's Avonex, an interferon-beta (IFN-beta) agent. According to surveyed neurologists, Copaxone's superior side-effect profile, particularly the lack of flu-like symptoms, is a key driver of its first-line...

2010-01-21 00:30:00

ROCKLAND, Mass., Jan. 21 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today the online publication of the results from the CLARITY(1) Phase III trial using Cladribine Tablets (EMD Serono's proprietary investigational oral formulation of cladribine) in The New England Journal of Medicine(2). The CLARITY study was a two-year (96-week), randomized, double-blind, placebo-controlled Phase III trial of Cladribine Tablets in 1,326 people with...

2010-01-11 11:00:00

EXTON, Pa., Jan. 11 /PRNewswire/ -- BioTrends Research Group, Inc. announces the release of the Wave One LaunchTrends(®): EXTAVIA report. The survey was completed by U.S. Neurologists (n=76) in November and December 2009, approximately one month following the launch of Novartis' Extavia (Interferon beta 1b). Awareness of Extavia is relatively high but familiarity is more moderate. Over one-third of current Extavia users indicate this newest agent will be a likely...

2009-12-16 07:00:00

ROCKLAND, Mass., Dec. 16 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, today announced a strategic collaboration with Brigham and Women's Hospital in Boston, to advance basic and clinical research in multiple sclerosis (MS), with the goal of generating new and innovative discoveries that advance treatment for people living with this condition. The multi-faceted agreement will run for up to 5 years, with the potential to renew the alliance thereafter. Both...

2009-11-30 08:06:00

ROCKLAND, Mass., Nov. 30 /PRNewswire/ -- EMD Serono, an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a refuse to file letter from the US Food and Drug Administration (FDA) on the New Drug Application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing forms of multiple sclerosis (MS). "The company will work closely with the FDA to fully understand FDA's concerns and define a...

2009-10-19 12:06:00

ROCKLAND, Mass., Oct. 19 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, marked the expansion of its research facility in Billerica, MA today, with a topping off ceremony. Executives from EMD Serono were joined by Congresswoman Niki Tsongas, Gregory Bialecki, Secretary of Housing and Development, State Representative William Greene and Marc T. Lombardo, Chairman of the Billerica Board of Selectman and other officials to commemorate the research expansion...

2009-10-05 09:46:00

ROCKLAND, Mass., Oct. 5 /PRNewswire/ -- EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that Science magazine has named it one of the world's leading biotechnology and pharmaceutical employers. EMD Serono's ranking improved to No. 6 this year, up from No. 7 in 2008 and No. 17 in 2007. "This is a great honor because the survey by Science sought opinions from people within the scientific community, people who actually know the biotech and pharmaceutical...

2009-09-30 11:02:00

ROCKLAND, Mass., Sept. 30 /PRNewswire/ -- EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced today the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for reducing relapses in people with relapsing forms of multiple sclerosis (MS). Cladribine Tablets has the potential to be the first orally administered...

2009-09-30 07:14:00

WALTHAM, Mass., Sept. 30 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient-targeted messaging for emerging multiple sclerosis oral agents will need to provide high-level information regarding the efficacy and preservation of quality of life and forego catchy and/or short taglines highlighting oral dosing. The knowledgeable multiple sclerosis patient population is likely to already...

2009-08-17 00:15:00

EAST HANOVER, N.J., Aug. 17 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved Extavia(R) (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from Novartis to help patients manage this devastating disease. Extavia is approved by the FDA for the treatment of relapsing forms of MS to reduce the frequency of clinical exacerbations. The therapy is also indicated for patients who have experienced a first clinical episode of MS...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'